ESCRS 2023: Presbyopia treatment with microporation therapeutic technology by Ace Vision Group
AnnMarie Hipsley, DPT, PhD, Founder and CEO of Ace Vision Group, met with Ophthalmology Times Europe at the 2023 European Society of Cataract and Refractive Surgeons to discuss Ace Vision Group’s microporation therapeutic technology, used to treat presbyopia.
Explore More Articles
Ace Vision Group Names Rob Kissling, MD, as Chief Medical Officer
Ace Vision Group announced that it has named Rob Kissling, MD, as Chief Medical Officer. Dr. Kissling has more than 20 years of experience integrating clinical development, medical strategy, and business planning to develop and commercialize devices and medicines for ophthalmology. His tenure has included companies such as Pharmacia, Pfizer, and Novartis. Most recently, he …
read moreIs Presbyopia Finally Taking Center Stage?
Presbyopia is the eye condition that will impact 100% of patients at some point. It has long been said that a solution for presbyopia is the “holy grail” of eye care. While there is not yet a cure for presbyopia, there are more tools than ever before to help patients have functional near and intermediate …
read moreInsights from Industry Innovators
Carey Powers caught up with five innovative companies at this years OIS XIV in San Diego, to discuss the latest advancements in ophthalmology on the OIS podcast. Topics included touchless laser therapy for presbyopia, extending the duration of intravitreal treatments, next-generation tear fluid testing, and new imaging methodologies for vitreoretinal conditions. Guests include: 🔹Alex Lopez, …
read more